Sharemaestro Newsreel

Why Myriad Genetics (MYGN) Shares Are Falling Today

Castle Biosciences (NASDAQ:CSTL) Releases Quarterly Earnings Results, Beats Expectations By $0.37 EPS

Castle Biosciences (NASDAQ:CSTL) Sees Strong Trading Volume After Earnings Beat

Is Veracyte (VCYT) Fully Valued After Raising 2026 Revenue Guidance?

Freedom Capital raises Veracyte stock price target on strong earnings

Mettler-Toledo International Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:MTD) 2026-07-31

Mettler-Toledo International (MTD) Earnings Date and Reports 2026 $MTD

Thermo Fisher (NYSE: TMO) lifts Q2 2026 revenue 10% and buys $9.1B Clario

Illumina (ILMN) Stock Climbs On Clinical Growth Despite Margin Pressure

Illumina, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ILMN) 2026-07-31

Illumina (ILMN) reported strong Q2 2026 earnings with revenue up 9.4% to $1.16 billion, exceeding analyst expectations. Gross profit increased to $770 million, and diluted earnings per share were $1.35 against an expectation of $1.25, leading to a 3.86% rise in the company's stock …

ILMN|Illumina Inc|Price:191.209|Chg%:+3.249

Guardant Health, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:GH) 2026-07-31

Thermo Fisher Scientific Inc (TMO) extends 12-week climb as turnover builds

The diagnostics and research group’s weekly context shows a sustained rebound, though the trend screen has not yet moved to active.

$GRAL Securities: Suffer Losses on Your GRAIL, Inc.

Bleichmar Fonti & Auld LLP has filed a class action lawsuit against GRAIL, Inc. (NASDAQ:GRAL) and its executives for securities fraud. The lawsuit alleges that GRAIL misled investors regarding its NHS-Galleri cancer trial, causing a 50% stock drop after the trial failed to meet …

Exagen Inc (XGN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Exagen Inc (XGN), highlighting its current valuation score of 7.83 and its ranking within the Healthcare Providers & Services industry. It details the company's P/E ratio, noting its current value relative to recent highs and lows. The …

Veracyte (VCYT) Q2 Earnings and Revenues Surpass Estimates

Veracyte (VCYT) reported strong Q2 results, with earnings of $0.54 per share and revenues of $150.32 million, both surpassing Zacks Consensus Estimates. The company has consistently exceeded EPS and revenue expectations over the past four quarters, and its stock has significantly outperformed the S&P …

Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know

Myriad Genetics Inc. (NASDAQ: MYGN) shares dropped significantly by 37.80% in after-hours trading after the company reported disappointing second-quarter 2026 financial results, including lower revenue, an operating loss, and reduced full-year revenue guidance. The company also suspended its adjusted EBITDA outlook. Despite the overall …

Bronstein, Gewirtz & Grossman, LLC Encourages Medpace Holdings, Inc. (MEDP) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of Medpace Holdings, Inc. (NASDAQ: MEDP) investors who purchased securities before April 22, 2025, concerning alleged corporate wrongdoing by the company's officers and/or directors. The firm encourages affected stockholders to contact them for …

Biodesix Inc (BDSX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Biodesix Inc (BDSX), noting its current price momentum score and suggesting it's suitable for range-bound swing trading with resistance at 24.41 and support at 18.59. It details various technical indicators like MACD, RSI, and moving averages (MA5 …

Precipio Inc (PRPO) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Precipio Inc (PRPO), detailing its current risk score of 2.96 within the Healthcare Equipment & Supplies industry. It highlights the company's beta value of 1.33, indicating higher volatility compared to the S&P 500. The assessment also covers …

Transcript : Veracyte, Inc., Q2 2026 Earnings Call, Jul 30, 2026

This article is a transcript of Veracyte, Inc.'s Q2 2026 Earnings Call held on July 30, 2026. The company reported increased Q2 non-GAAP earnings and revenue, leading to a raised revenue guidance for the full year 2026. The transcript includes opening remarks and indicates …

Labcorp Q2 2026 slides: strong results drive guidance raise

Labcorp (NYSE:LH) reported strong Q2 2026 results, surpassing Wall Street expectations with adjusted earnings of $4.99 per share and revenue of $3.73 billion. This performance led the company to raise its full-year guidance for 2026. Key drivers included robust organic growth, operational efficiency gains, …

FRNM | Freenome, Inc. Common stock Stock Data, Price & News

Castle Biosciences, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CSTL)

Castle Biosciences, Inc. released its Q2 2026 earnings call presentation. The company reported an EPS of -$0.07, beating estimates by $0.34, and revenue of $103.55M, an increase of 20.14% year-over-year, beating estimates by $17.30M. This report accompanies their earnings call from July 31, 2026.

CareDx Announces Second Quarter 2026 Financial Results

CareDx, Inc. reported strong second-quarter 2026 financial results, with a 52% year-over-year revenue increase to $132 million and GAAP net income of $111 million. The company raised its full-year 2026 revenue guidance to $490 million to $500 million and adjusted EBITDA guidance to $66 …

Myriad Genetics Lowers FY26 Rev Outlook

Myriad Genetics announced a reduction in its revenue outlook for fiscal year 2026. The company did not provide specific reasons for the revised forecast in the provided content.

Myriad Genetics Reports Second Quarter 2026 Financial Results; Deploying New Initiatives Focused on Driving Increased Efficiency, Productivity and Scalability

Myriad Genetics announced its second quarter 2026 financial results, with revenue of $190.7 million, an 11% decrease year-over-year. The company is implementing new initiatives, including "Ascend," to improve efficiency, productivity, and scalability, and revised its full-year 2026 financial guidance. Despite challenges in Prenatal Health …

BlackRock (NEO holder) discloses 20.4M-share NeoGenomics stake in latest update

BlackRock, Inc. has filed an amended beneficial ownership report revealing a 15.6% stake in NeoGenomics, Inc., totaling 20,358,331 shares. Of these, BlackRock holds sole voting power over 19,688,877 shares and sole dispositive power over all 20,358,331 shares. The filing also notes that the iShares …

Myriad Genetics Q2 Results: Revenue falls 11% YoY

Myriad Genetics Inc. experienced an 11% year-over-year revenue decline to $190.7 million in Q2 2026, leading to a significant 37.8% drop in stock price. The company reported a $38.9 million operating loss and suspended its full-year adjusted EBITDA guidance due to payer friction and …

Veracyte posts 15% revenue surge in Q2, raises FY26 guidance

Veracyte Inc. reported a strong Q2 2026 with a 15% revenue increase, reaching $150.3 million, and a significant turnaround to a GAAP net income of $25.5 million. Driven by robust demand for its cancer diagnostics portfolio, particularly Decipher Prostate and Afirma tests, the company …

Fulgent Genetics cuts FY26 revenue guidance amid billing delays

Fulgent Genetics reported Q2 2026 revenue of $85.4 million and a non-GAAP loss of $16.2 million, missing analyst estimates. The company lowered its full-year 2026 revenue guidance to $330-$340 million and non-GAAP loss to $63-$67 million, attributing the revisions to delays in its billing …

Myriad Genetics (NASDAQ: MYGN) posts Q2 loss, lowers 2026 revenue view

Myriad Genetics (NASDAQ: MYGN) reported a Q2 2026 net loss of $43.2 million on revenues of $190.7 million, marking an 11% year-over-year decline. The company also lowered its full-year 2026 revenue guidance to $770–$790 million and suspended its Adjusted EBITDA outlook, citing challenges in …

Mdxhealth schedules live Q&A on second-quarter results Aug. 13

Mdxhealth (NASDAQ: MDXH) will release its second-quarter 2026 financial results after market close on Thursday, August 13, 2026. The company will host a conference call and webcast with a live Q&A session at 4:30 PM ET / 22:30 CET, with a replay available on …

KAPA|Kairos Pharma Ltd|Price:0.297|Chg%:-0.003

This article provides a comprehensive stock analysis of Kairos Pharma Ltd (KAPA) from TradingKey. It highlights the company's strong fundamentals and high growth potential, despite being currently assessed as fairly valued within the Biotechnology & Medical Research industry. The analysis also notes high institutional …

Fulgent Genetics Q2 Earnings Call Highlights

Fulgent Genetics reported second-quarter 2026 revenue of $85.4 million, a 20% sequential increase, but faced challenges from billing system transition issues that pressured collections and gross margins, leading to a $29.5 million GAAP net loss. The company lowered its 2026 revenue guidance to $330 …

Illumina Earnings: Strong Instrument Sales and Growing AI Opportunities Boost 2026 Outlook